The size of the global in-vitro toxicology testing market value is expected to reach USD 35712 Million by 2025 from USD 18418 Million in 2020, growing at a CAGR of 14.16%.
In-vitro toxicology testing is the scientific analysis of toxic effects produced by chemical substances on cultured mammalian cells or bacteria. Toxicity testing is essential in drug discovery as it identifies the poisonous effects of the new compound in the early stages of drug discovery. This early detection of toxicity reduces the development cost and time.
MARKET DRIVERS
Increasing technological advancements, rising research & development in cell culture, growing demand for in-vitro toxicology tests over the conventional in-vivo tests are majorly expanding the in-vitro toxicology testing market size. Increasing awareness of toxicity testing studies, expanding health-consciousness amongst individuals and improving economic status in emerging nations, the existence of favorable regulatory authorities for toxicology testing using the in-vitro tests drives the growth of the market.
Synergetic relationships between different stakeholders and an increase in toxicology databases facilitating the use of in-vitro test methods are regarded to offer essential growth opportunities for the players in the global in-vitro toxicology testing market. Developing condition-specific makers, tests, and increasing demand for IVD products in existing countries provide significant opportunities for the various stakeholders. GEM, which is Growth Engagement Model, aims to create or control the action of working with the clients to establish new opportunities.
MARKET RESTRAINTS
However, scarcity of in-vitro models to detect immunostimulation & autoimmunity, lack of predictive ability of in vitro testing over in vivo testing, technological advancements limiting the use & decreasing adoption rate are the significant factors restrain the growth of in-vitro toxicology testing market.
REPORT COVERAGE
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2019 to 2025 |
|
Base Year |
2019 |
|
Forecast Period |
2020 to 2025 |
|
Segments Covered |
By Product, Type, Toxicity Endpoints and tests, Metahod, Technology, Industry, Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
This market research report on the global in-vitro toxicology testing market has been segmented and sub-segmented based on the product, type, toxicity endpoints and tests, method, technology, industry, region.
In-Vitro Toxicology Testing Market – By Product
Based on the product, the Assays segment is estimated to command the largest share of the global in-vitro toxicology testing market by product in 2019. This segment is strongly driven by an increasing number of in-vitro tests being performed worldwide, which leads to the recurrent purchase of reagents and other labware.
In-Vitro Toxicology Testing Market – By Type
Based on the type, the ADME segment is predicted to stand top in leading max shares in the market during the forecast period due to a growing number of early stages in vitro ADME examining tests in preventing failure.
In-Vitro Toxicology Testing Market – By Toxicity Endpoints & Tests
Based on Toxicity Endpoints & Tests, the Systemic toxicity segment is estimated to command the largest share of the global in-vitro toxicology testing market as multiple organ development with assumed blood flow for assessing systemic toxicity drives the segment growth.
The Dermal toxicity segment is next in line in having a considerable growth rate throughout the forecast period. The dermal toxicology is simple, easy, reliable, and cost-effective. Moreover, advancement related to tools for dermal toxicity and risk assessment is projected to surge the segment growth globally.
In-Vitro Toxicology Testing Market – By Technology
Based on technology, the cell culture technology segment is projected to dominate the market globally. It is an excellent model for screening toxic effects as it offers consistent samples and reproducible results. Moreover, it supports the tissue-specific function, which urges cell proliferation.
However, the OMICS technologies segment is projected to have the highest CAGR during the forecast period as it provides personalized toxicology data, understanding the toxicity of nano-sized materials.
In-Vitro Toxicology Testing Market – By Method
Based on the method, the In-silico method is estimated to command the largest share of the global in-vitro toxicology testing market by the method in 2019. The wide accessibility of the technology boosts this segment for the pharmacokinetics of drugs. Pharmaceutical and biotechnology companies are important-significantly dependent on cellular assays for toxicity screening.
In-Vitro Toxicology Testing Market – By Industry
Based on industry, the cosmetics & household products industry accounted for the largest market share of the global in-vitro toxicology testing market by sector in 2019.
However, the pharmaceutical segment is expected to dominate the market during the forecast period as the rise influences this segment in support of the government. The launch of innovative drugs with advanced technologies is mainly surging the demand for this segment.
The chemical industry is expected to witness lucrative growth over the forecast period due to continuous advancements in toxicity profiling and safety assessment.
In-Vitro Toxicology Testing Market – By Region
Globally, the European region is estimated to account for the largest share of 32.5% of the global in-vitro toxicology testing market in 2019. In contrast, Asia-Pacific is expected to grow at the highest CAGR of 16.10% during the forecast period.
North America is anticipated to dominate the global IVTT market over the forecast period. Support from the government regulations and adoption of technological advancements are propelling the demand of the market. The U.S. is leading the market in this region because of developments in genetics and genetic screening approaches and the emergence of a new 3D cell culture approach.
Europe is expected to account for the largest share in the In-Vitro toxicology testing market, and Germany is anticipated to dominate and have the largest share in this region. France is expected to grow with the highest CAGR over the forecast period.
Asia-Pacific is estimated to grow with the highest CAGR in the In-Vitro toxicology testing market during the forecast period. The growth is attributed to the emergence of CROs for outsourcing toxicology relevant research projects and increasing consumer awareness of product safety.
Latin America is expected to have a commendable share in the IVTT. An increasing number of an aging population, investments in research, and development influence the research over the cell culture. Brazil is leading the IVTT market.
The Middle East & Africa region is expected to have small and minimal growth in the IVTT market due to demand for advanced technologies and the appearance of various analytical methods over bioinformatics and biotechnology.
TOP COMPANIES IN THE GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET
The key players in global in-vitro toxicology testing market include Covance, Inc. (A subsidiary of LabCorp) (U.S.), Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Eurofins Scientific SE (Luxembourg), General Electric Company (U.S.), BioReliance, Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Catalent (U.S.), and Cyprotex (U.K.), among others.
KEY HAPPENINGS IN THIS MARKET IN THE RECENT PAST:
On February 20, 2020, Catalent Inc., the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced its wholly-owned subsidiary, Catalent Pharma Solutions.
On March 27, 2018, BioIVT, a leading provider of biospecimens and related services, announced that it had acquired Ascendance Biotechnology, Inc., which was formed in 2015 from the merger of Hepregen Corporation and the ESI BIO products division of BioTime Inc. to develop a multi-national cell-based company.
On December 28, 2016, Ascendance Biotechnology Inc., a leader in the commercialization of In-Vitro cell-based products and stem-related laboratory products, announced the agreement with GE healthcare providing a right to manufacture, market and sell the GE Healthcare Cytivaof human stem cell-derived and heart muscle cells used for evaluating potential cardiotoxicity.
On December 06, 2015, BioTime Inc. regenerative medicine company, and Hepregen Corporation, announced the formation of Ascendance Biotechnology Inc. Ascendance combines Hepregen’s application–directed, cellular micro-patterning drug and chemical screening technologies with BioTime’s ESI BIO research products and proprietary stem cell-based technologies.
On January 31, 2012, Sigma-Aldrich, a leading Life Science and High Technology company, announced that it had completed its acquisition of Bio reliance Holdings Inc., a leading provider of biopharmaceutical testing services, from Avista Capital Partners.
Please go for the sample to get access to the List of Figures and Tables of the report.
Related Reports
